Tuesday, April 17, 2018 12:05:53 PM
NWBO's management has been inept in managing its affairs. Since 2015 NWBO's market cap has fallen from nearly $1 billion dollars to less than $100 million. Because of a lack of a competent CPA/CFO, NWBO botched the maintenance of its Most Favored Nation (MFN) strategy with its privately-owned manufacturer, Cognate. This resulted in NWBO being forced off of the respected and well-regulated NASDAQ exchange to the free-wheeling, less regulated/respected OTC exchange. To make matters even worst, management elected to not raise funding when its stock price had appreciated 100+% even though it had 1 institutional investor at the time, limited cash on hand and a high burn rate due to the ongoing cost of its muti-continent DCVax-L phase III trial. This error in judgement forced NWBO to raise funds while the price per share (pps) of its stock was at penny stock levels, diluting the value of this company to unrecoverable levels. The number of shares outstanding increased from approx. 170 million to, now, 1 billion. NWBO's pps plummeted from a high of $12 to its current price of 22 cents. Despite its dismal performance, management is seeking, via the upcoming proxy vote, to "reward" three of its directors with 16 million shares (on top of the 141 million its 7 officers and directors already own). Management should be too embarrassed to even ask for a "reward", given its dismal performance.
NWBO PR'd an internal investigation in "90 days" 2 years ago, the trial OS threshold in "several months" 10 months ago, a "multi-month" process to move to datalock 10 months ago. Why can't they provide the info?
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM